NI201000083A - Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales. - Google Patents
Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales.Info
- Publication number
- NI201000083A NI201000083A NI201000083A NI201000083A NI201000083A NI 201000083 A NI201000083 A NI 201000083A NI 201000083 A NI201000083 A NI 201000083A NI 201000083 A NI201000083 A NI 201000083A NI 201000083 A NI201000083 A NI 201000083A
- Authority
- NI
- Nicaragua
- Prior art keywords
- breast cancer
- combination
- nitrobenzamide
- iodo
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En un aspecto, la presente invención proporciona un método para tratar el cáncer de mama que es negativo para al menos uno de ER, PR, o HER2, que comprende administrar a un sujeto al menos un inhibidor de PARP. En otro aspecto, la presente invención proporciona un método para tratar el cáncer de mama, que comprende administrar a un sujeto al menos un inhibidor de PARP en combinación con al menos un agente anti-tumoral.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98733307P | 2007-11-12 | 2007-11-12 | |
US1236407P | 2007-12-07 | 2007-12-07 | |
US5852808P | 2008-06-03 | 2008-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201000083A true NI201000083A (es) | 2011-04-27 |
Family
ID=40639414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201000083A NI201000083A (es) | 2007-11-12 | 2010-05-11 | Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales. |
Country Status (23)
Country | Link |
---|---|
US (3) | US7732491B2 (es) |
EP (1) | EP2217227B1 (es) |
JP (1) | JP2011503111A (es) |
KR (1) | KR20100102609A (es) |
CN (2) | CN103169973A (es) |
AR (1) | AR069291A1 (es) |
AU (1) | AU2008321128A1 (es) |
CA (1) | CA2705537A1 (es) |
CO (1) | CO6290650A2 (es) |
CR (1) | CR11485A (es) |
DO (2) | DOP2010000141A (es) |
EC (1) | ECSP10010240A (es) |
GT (1) | GT201000140A (es) |
IL (1) | IL205689A0 (es) |
MA (1) | MA31909B1 (es) |
MX (1) | MX2010005222A (es) |
NI (1) | NI201000083A (es) |
NZ (1) | NZ586125A (es) |
RU (2) | RU2480211C2 (es) |
SG (1) | SG185952A1 (es) |
TN (1) | TN2010000208A1 (es) |
TW (2) | TW200924739A (es) |
WO (1) | WO2009064738A2 (es) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ587586A (en) * | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
US8143447B2 (en) * | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
CN101534836B (zh) * | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
AU2007292302A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing PARP inhibitors and uses thereof |
US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
NZ586125A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
WO2009064444A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
CN101888777A (zh) * | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
EP2250282A4 (en) * | 2008-02-04 | 2011-05-18 | Bipar Sciences Inc | METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES |
CA2723587C (en) * | 2008-05-27 | 2017-09-26 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
WO2010118324A2 (en) | 2009-04-09 | 2010-10-14 | Nuclea Biotechnologies, LLC | Antibodies against fatty acid synthase |
WO2011031517A1 (en) | 2009-08-27 | 2011-03-17 | Nuclea Biotechnologies, LLC | Method and assay for determining fas expression |
US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
EP2558866B1 (en) * | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
DK3327148T3 (da) * | 2010-06-18 | 2021-04-12 | Myriad Genetics Inc | Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle |
WO2012012454A1 (en) * | 2010-07-19 | 2012-01-26 | Bipar Sciences, Inc. | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
AU2011293635B2 (en) | 2010-08-24 | 2015-11-26 | Children's Medical Center Corporation | Methods for predicting anti-cancer response |
US20140315973A1 (en) * | 2010-10-07 | 2014-10-23 | Agency For Science, Technology And Research | Parp-1 inhibitors |
RU2565079C2 (ru) | 2010-11-05 | 2015-10-20 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Бензамидные производные, обладающие противораковой активностью, способ их получения и их применение |
US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
EP2670866A4 (en) * | 2011-04-05 | 2015-09-02 | Translational Genomics Res Inst | BIOMARKERS AND METHODS OF USE |
WO2012155063A1 (en) * | 2011-05-11 | 2012-11-15 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
EP2717911A1 (en) | 2011-06-06 | 2014-04-16 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
JP6117194B2 (ja) | 2011-06-17 | 2017-04-19 | ミリアド・ジェネティックス・インコーポレイテッド | アレル不均衡を評価するための方法および材料 |
US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
WO2013025418A1 (en) * | 2011-08-15 | 2013-02-21 | Morehouse School Of Medicine | Delivery system for specifically targeting cancer cells and method of use thereof |
FI20115876A0 (fi) * | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
AU2012316266B2 (en) * | 2011-09-26 | 2015-07-30 | Celgene Corporation | Combination therapy for chemoresistant cancers |
AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
WO2013096843A1 (en) | 2011-12-21 | 2013-06-27 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
US8889707B2 (en) * | 2012-02-08 | 2014-11-18 | Malka COHEN-ARMON | Treatment of addiction |
WO2013130347A1 (en) | 2012-02-23 | 2013-09-06 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
EA032345B1 (ru) * | 2012-06-01 | 2019-05-31 | Берг Ллк | Способ лечения рака с использованием кофермента q10 |
EP2859118B1 (en) | 2012-06-07 | 2017-11-22 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
US10308986B2 (en) | 2013-03-14 | 2019-06-04 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
WO2014152330A1 (en) * | 2013-03-15 | 2014-09-25 | Stc.Unm | Arsenic-based treatment of cancers and inflammatory disorders |
WO2014150840A1 (en) * | 2013-03-15 | 2014-09-25 | Medimmune, Llc | Methods of treating breast cancer |
AU2014251043B2 (en) | 2013-04-09 | 2020-01-16 | The Board Of Regents Of The University Of Texas System | Tumor-selective combination therapy |
ES2909899T3 (es) | 2013-12-09 | 2022-05-10 | Inst Curie | Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos |
US10653689B2 (en) | 2014-01-14 | 2020-05-19 | Nektar Therapeutics | Combination-based treatment method |
EP3137076A4 (en) * | 2014-05-02 | 2017-12-06 | Emory University | Selective chemotherapy treatments and diagnostic methods related thereto |
US9303069B2 (en) * | 2014-05-05 | 2016-04-05 | University Of Mississippi Medical Center | Peptides for treating cancer |
WO2016025958A1 (en) | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
BR112017012142A2 (pt) * | 2014-12-12 | 2018-01-02 | Medivation Prostate Therapeutics Inc | método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama |
CN109121418A (zh) | 2015-03-02 | 2019-01-01 | 西奈健康系统 | 同源重组因子 |
JP6927890B2 (ja) * | 2015-06-12 | 2021-09-01 | ジェネア アイピー ホールディングス ピーティーワイ リミテッド | 患者および生物学的試料の識別ならびに追跡のための方法およびシステム |
WO2017081171A1 (en) * | 2015-11-10 | 2017-05-18 | Paracrine Therapeutics Ab | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
WO2017174879A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Oulu | Compounds for use in the treatment of cancer |
US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
EP3589661B1 (en) | 2017-03-02 | 2023-11-01 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
WO2018170457A1 (en) * | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
WO2018183947A1 (en) | 2017-03-31 | 2018-10-04 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
CN111093708A (zh) * | 2017-04-07 | 2020-05-01 | 坦伯公司 | 生物正交组合物 |
AU2018264992A1 (en) * | 2017-05-09 | 2019-12-05 | Merck Sharp & Dohme B.V. | Combination therapies for treating cancer |
EP3624850A1 (en) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Combination therapies for treating cancer |
US11433074B2 (en) | 2017-06-22 | 2022-09-06 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
WO2019051025A2 (en) * | 2017-09-06 | 2019-03-14 | The Trustees Of Columbia University In The City Of New York | TREATMENT OF AGGRESSIVE CANCERS BY TARGETING C9ORF72 |
US11628144B2 (en) | 2017-09-29 | 2023-04-18 | Triact Therapeutics, Inc. | Iniparib formulations and uses thereof |
JP2020536066A (ja) | 2017-09-30 | 2020-12-10 | テサロ, インコーポレイテッド | 癌を治療するための併用療法 |
MX2020003799A (es) * | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
EP3709981A4 (en) * | 2017-11-15 | 2021-08-11 | The Regents of the University of California | METHOD OF TREATMENT OF EXTRACHROMOSOMAL DNA EXPRESSING CANCER |
MA51821A (fr) * | 2018-02-12 | 2020-12-23 | Cinda Pharma Ab | Inhibiteurs de la thiorédoxine réductase à utiliser dans le traitement du cancer |
US10953209B2 (en) * | 2018-03-28 | 2021-03-23 | Board Of Regents Of The University Of Texas System | Treating tumors using TTFields combined with a PARP inhibitor |
US20190375732A1 (en) * | 2018-05-14 | 2019-12-12 | David Hung | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
SG11202105770YA (en) | 2018-12-19 | 2021-07-29 | Corcept Therapeutics Inc | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
EP3927345A4 (en) | 2019-02-22 | 2022-12-21 | Corcept Therapeutics Incorporated | THERAPEUTIC USES OF RELACORILANT, A GLUCOCORTICOID RECEPTOR MODULATOR DERIVED FROM AZADECALIN FUSED TO A HETEROARYL KETONE |
WO2020232133A1 (en) * | 2019-05-14 | 2020-11-19 | Georgetown University | Methods of treating gastrointestinal cancers and tumors thereof using combination therapy |
CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US20220387483A1 (en) * | 2019-11-04 | 2022-12-08 | Faraday Pharmaceuticals, Inc. | Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CA3166386A1 (en) * | 2019-12-31 | 2021-07-08 | Kinnate Biopharma Inc. | Treatment of cancer with cdk12/13 inhibitors |
CN111362828A (zh) * | 2020-03-30 | 2020-07-03 | 山西医科大学 | 一种18f标记的氟丙酰化鸟氨酸及其制备方法和应用 |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
US20230190841A1 (en) * | 2021-12-22 | 2023-06-22 | Laura Mann Kevehazi | Herbal composition for breast cancer prevention |
WO2024016014A2 (en) * | 2022-07-15 | 2024-01-18 | Lantern Pharma Inc. | Method for treating breast cancers and parp resistant breast cancers |
Family Cites Families (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2669583A (en) * | 1954-02-16 | X-amroo-zralkoxbbenzamdjes | ||
US2006735A (en) * | 1932-11-17 | 1935-07-02 | Gen Aniline Works Inc | Nitro-aryl amino-aryl amines |
NL247377A (es) * | 1957-11-25 | |||
US3161564A (en) | 1960-10-03 | 1964-12-15 | Salsbury S Lab Dr | Veterinary composition containing halo-nitro-benzamides and methods of using same |
US3228833A (en) * | 1962-12-17 | 1966-01-11 | Sterling Drug Inc | Anticoccidial compositions and methods of using same |
AR204004A1 (es) | 1973-04-02 | 1975-11-12 | Lilly Co Eli | Procedimientos para preparar derivados de vinblastina leurosidina y leurocristina |
FR2456731A1 (fr) | 1979-05-16 | 1980-12-12 | Choay Sa | Nouveaux derives substitues d'ary |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5032617A (en) * | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) * | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
ES2056790T3 (es) * | 1986-01-17 | 1994-10-16 | Preventive Medicine Inst | Ensayo para determinar la predisposicion o susceptibilidad a enfermedades asociadas con dna. |
US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
US5223608A (en) * | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US4923885A (en) * | 1988-08-19 | 1990-05-08 | Merck & Co., Inc. | 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents |
US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
JPH05503073A (ja) | 1989-09-26 | 1993-05-27 | オクタマー,インコーポレイテッド | ウイルス性疾患の治療に有用な6―アミノ―1,2―ベンゾピロン |
US5719151A (en) * | 1990-05-04 | 1998-02-17 | Shall; Sydney | Substituted benzene compounds |
US5633282A (en) * | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
US5232735A (en) | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
US5631038A (en) * | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
ATE186461T1 (de) * | 1990-09-28 | 1999-11-15 | Smithkline Beecham Corp | Verfahren zur herstellung wasserlöslicher camptothecinanaloge, sowie die verbindungen 10- hydroxy-11-c(1-6)-alkoxycamptothecin |
US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
US5247089A (en) | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
US5243050A (en) | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
US5162532A (en) | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
AU1746392A (en) | 1991-04-10 | 1992-11-17 | Octamer, Inc. | A method for inhibition of retroviral replication |
US5877185A (en) * | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
US5516941A (en) * | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
US5482975A (en) * | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
US5473074A (en) | 1991-10-22 | 1995-12-05 | Octamer, Incorporated | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54 |
US5652260A (en) * | 1991-10-22 | 1997-07-29 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
US5464871A (en) | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
DK0666868T4 (da) | 1992-10-28 | 2006-09-18 | Genentech Inc | Anvendelse af anti-VEGF-antistoffer til behandling af cancer |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
US5783599A (en) * | 1993-02-24 | 1998-07-21 | Octamer Inc | Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones |
DZ1781A1 (fr) | 1993-05-21 | 2002-02-17 | Radopah Ltd | Agents d'arylation. |
JP3025602B2 (ja) * | 1993-05-21 | 2000-03-27 | デビオファーム エス.アー. | 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法 |
US6008250A (en) | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
US6015792A (en) * | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
ATE225173T1 (de) | 1995-08-02 | 2002-10-15 | Univ Newcastle Ventures Ltd | Benzimidazol verbindungen |
JP3154399B2 (ja) | 1996-07-04 | 2001-04-09 | デビオファーム エス.アー. | 白金化合物の製造方法 |
US5837729A (en) | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
RU2103260C1 (ru) * | 1996-04-26 | 1998-01-27 | Государственный научный центр Российской Федерации "НИОПИК" | Способ получения 4-нитробензамида |
US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
JP2001518935A (ja) * | 1997-03-26 | 2001-10-16 | バイオソース テクノロジーズ,インコーポレイティド | 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体 |
US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
US6235748B1 (en) * | 1997-09-03 | 2001-05-22 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6514983B1 (en) * | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6426415B1 (en) * | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US6121278A (en) | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US5922775A (en) | 1997-10-23 | 1999-07-13 | Octamer, Inc. | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
US6380193B1 (en) * | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
AU9297998A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
CO5070700A1 (es) | 1998-06-05 | 2001-08-28 | Basf Ag | Genes novedosos de (adp-ribosa) polimerasa |
PT1127052E (pt) | 1998-11-03 | 2005-04-29 | Abbott Gmbh & Co Kg | 2-fenilbenzimidazois substituidos sua preparacao e aplicacao |
ES2216625T3 (es) | 1998-11-27 | 2004-10-16 | ABBOTT GMBH & CO. KG | Bencimidazoles substituidos y su empleo como inhibidores de parp. |
JP3552934B2 (ja) | 1998-12-24 | 2004-08-11 | セントラル硝子株式会社 | 安息香酸アミド類の製造方法 |
US6326517B1 (en) | 1998-12-10 | 2001-12-04 | Central Glass Company, Limited | Method of producing benzamides |
US6387902B1 (en) * | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
US6201020B1 (en) * | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
CZ302941B6 (cs) | 1999-01-11 | 2012-01-25 | Agouron Pharmaceuticals, Inc. | Tricyklická sloucenina a farmaceutický prostredek s jejím obsahem |
AU3076700A (en) * | 1999-01-26 | 2000-08-18 | Ono Pharmaceutical Co. Ltd. | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
US6423696B1 (en) * | 1999-04-16 | 2002-07-23 | The United States Of America, As Represented By The Department Of Health & Human Services | Inhibition of arylamine N-acetyl transferase |
DE19921567A1 (de) * | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6277990B1 (en) | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
WO2001090077A1 (en) * | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
ITMI20002358A1 (it) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
JPWO2002055076A1 (ja) | 2001-01-04 | 2004-05-13 | 第一製薬株式会社 | シクロデキストリン製剤 |
US20020164633A1 (en) | 2001-04-20 | 2002-11-07 | Inotek Pharmaceuticals Corporation | Cell-based assay for detecting activation of poly (ADP-ribose) polymerase |
CA2444531A1 (en) | 2001-05-08 | 2002-11-14 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
WO2003015785A1 (en) | 2001-08-15 | 2003-02-27 | Icos Corporation | 2h-phthalazin-1-ones and methods for use thereof |
US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
JPWO2003080077A1 (ja) | 2002-03-26 | 2005-07-21 | 萬有製薬株式会社 | 抗腫瘍性インドロピロロカルバゾール誘導体と他の抗がん剤との併用 |
US20040034078A1 (en) * | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
AU2003287526A1 (en) | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
WO2004087713A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
US7638605B2 (en) * | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
AU2004242947B2 (en) * | 2003-05-28 | 2010-04-29 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
US20050004038A1 (en) * | 2003-06-27 | 2005-01-06 | Lyon Robert P. | Bivalent inhibitors of Glutathione-S-Transferases |
DK1660095T3 (da) | 2003-07-25 | 2010-05-25 | Cancer Rec Tech Ltd | Tricykliske PARP-inhibitorer |
AU2004266572A1 (en) * | 2003-08-01 | 2005-03-03 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
JP2007504238A (ja) * | 2003-09-04 | 2007-03-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ポリ(adp−リボース)ポリメラーゼ(parp)の阻害剤としての置換インドール |
WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
BRPI0416206A (pt) | 2003-11-20 | 2006-12-26 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose) |
JP4864717B2 (ja) | 2003-11-20 | 2012-02-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ(adp−リボース)ポリメラーゼインヒビターとしての7−フェニルアルキル置換2−キノリノンおよび2−キノキサリノン |
NZ547984A (en) | 2003-12-01 | 2009-03-31 | Kudos Pharm Ltd | DNA damage repair inhibitors for treatment of cancer |
CN1890224B (zh) | 2003-12-05 | 2011-06-08 | 詹森药业有限公司 | 用作聚(adp-核糖)聚合酶抑制剂的6-取代的2-喹啉酮和2-喹喔啉酮 |
EA010592B1 (ru) | 2003-12-10 | 2008-10-30 | Янссен Фармацевтика Н.В. | 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы |
US7439031B2 (en) * | 2003-12-15 | 2008-10-21 | The Trustees Of The University Of Pennsylvania | Method of identifying compounds that induce cell death by necrosis |
US7680864B2 (en) | 2004-03-02 | 2010-03-16 | Intel Corporation | Method and apparatus for managing access to stored objects based on retention policy |
PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
JP2005336083A (ja) | 2004-05-26 | 2005-12-08 | Sumitomo Chemical Co Ltd | 芳香族アミノ化合物の製造方法 |
AU2005259190B2 (en) | 2004-06-30 | 2011-05-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as PARP inhibitors |
ES2563954T3 (es) | 2004-06-30 | 2016-03-16 | Janssen Pharmaceutica Nv | Derivados de ftalazina como inhibidores de PARP |
EA012416B1 (ru) | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
US20060035890A1 (en) | 2004-08-10 | 2006-02-16 | Amit Banerjee | Compounds and methods for the treatment of ubiquitin conjugating disorders |
GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
MX2007003314A (es) * | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
WO2006033007A2 (en) * | 2004-09-22 | 2006-03-30 | Pfizer Inc. | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
US7713973B2 (en) * | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
DE102004050196A1 (de) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
US20060094676A1 (en) * | 2004-10-29 | 2006-05-04 | Ronit Lahav | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
CA2585638C (en) | 2004-10-29 | 2014-05-06 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having aurora a selective inhibitory action |
CN1768733A (zh) | 2004-11-02 | 2006-05-10 | 上海富海科申药业有限公司 | 芳香硝基化合物在制备治疗艾滋病药物中的应用 |
CN1768732A (zh) | 2004-11-02 | 2006-05-10 | 上海富海科申药业有限公司 | 芳香硝基化合物在制备治疗肿瘤药物中的应用 |
US20070157330A1 (en) * | 2004-12-07 | 2007-07-05 | Min Wu | Reconstituted human breast tumor model |
GB0428111D0 (en) | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
CA2612979A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
NZ587586A (en) | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
WO2007041357A1 (en) * | 2005-09-29 | 2007-04-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
US20080293795A1 (en) | 2006-01-17 | 2008-11-27 | Abbott Laboratories | Combination therapy with parp inhibitors |
CN101370497B (zh) | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | 包含parp抑制剂和细胞毒性剂的联合产品及用途 |
EP3056196A1 (en) | 2006-03-22 | 2016-08-17 | SynCore Biotechnology CO., LTD | Treatment of triple receptor negative breast cancer |
CA2647545C (en) * | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
CA2655257A1 (en) | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20080262062A1 (en) | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
DE102006037399A1 (de) * | 2006-08-10 | 2008-02-14 | Archimica Gmbh | Verfahren zur Herstellung von Arylaminen |
US8143447B2 (en) | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
AU2007292302A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing PARP inhibitors and uses thereof |
CN101534836B (zh) * | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
CN101190211B (zh) | 2006-11-23 | 2011-08-10 | 上海富海科申药业有限公司 | 芳香硝基化合物在制备治疗病毒性肝炎药物中的应用 |
RS58936B1 (sr) | 2007-01-10 | 2019-08-30 | Msd Italia Srl | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
UA100852C2 (ru) | 2007-01-16 | 2013-02-11 | Байпар Сайенсиз, Инк. | Композиции для лечения рака |
AU2008223793B2 (en) | 2007-03-08 | 2012-08-23 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ,インコーポレイティド | ベンゾピロン系parp阻害剤を用いる癌の処置方法および組成物 |
WO2009064444A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
NZ586125A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
CN101888777A (zh) | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
-
2008
- 2008-11-11 NZ NZ586125A patent/NZ586125A/xx not_active IP Right Cessation
- 2008-11-11 RU RU2010123884/14A patent/RU2480211C2/ru not_active IP Right Cessation
- 2008-11-11 JP JP2010533334A patent/JP2011503111A/ja not_active Abandoned
- 2008-11-11 SG SG2012081568A patent/SG185952A1/en unknown
- 2008-11-11 US US12/269,024 patent/US7732491B2/en not_active Expired - Fee Related
- 2008-11-11 EP EP08849309.3A patent/EP2217227B1/en active Active
- 2008-11-11 AU AU2008321128A patent/AU2008321128A1/en not_active Withdrawn
- 2008-11-11 CN CN2013100532333A patent/CN103169973A/zh not_active Withdrawn
- 2008-11-11 MX MX2010005222A patent/MX2010005222A/es active IP Right Grant
- 2008-11-11 CA CA2705537A patent/CA2705537A1/en not_active Withdrawn
- 2008-11-11 WO PCT/US2008/083147 patent/WO2009064738A2/en active Application Filing
- 2008-11-11 CN CN2008801245719A patent/CN101917982B/zh not_active Withdrawn - After Issue
- 2008-11-11 KR KR1020107013013A patent/KR20100102609A/ko not_active Application Discontinuation
- 2008-11-12 TW TW097143777A patent/TW200924739A/zh unknown
- 2008-11-12 TW TW101129769A patent/TW201249430A/zh unknown
- 2008-11-12 AR ARP080104935A patent/AR069291A1/es unknown
-
2009
- 2009-07-01 US US12/496,593 patent/US20100003192A1/en not_active Abandoned
-
2010
- 2010-05-11 TN TN2010000208A patent/TN2010000208A1/fr unknown
- 2010-05-11 IL IL205689A patent/IL205689A0/en unknown
- 2010-05-11 GT GT201000140A patent/GT201000140A/es unknown
- 2010-05-11 NI NI201000083A patent/NI201000083A/es unknown
- 2010-05-12 DO DO2010000141A patent/DOP2010000141A/es unknown
- 2010-06-08 EC EC2010010240A patent/ECSP10010240A/es unknown
- 2010-06-10 CR CR11485A patent/CR11485A/es not_active Application Discontinuation
- 2010-06-11 CO CO10070938A patent/CO6290650A2/es not_active Application Discontinuation
- 2010-06-11 MA MA32906A patent/MA31909B1/fr unknown
-
2012
- 2012-03-26 US US13/430,475 patent/US20120269861A1/en not_active Abandoned
- 2012-11-16 DO DO2012000291A patent/DOP2012000291A/es unknown
- 2012-12-13 RU RU2012153963/14A patent/RU2012153963A/ru unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201000083A (es) | Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales. | |
NI201000084A (es) | Tratamiento de cáncer de ovarios con un compuesto yodonitrobenzamida en combinación con agentes anti-tumorales | |
CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
AR077866A1 (es) | Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina | |
NI201200179A (es) | Métodos de tratamiento contra el cáncer pancreático | |
ECSP109918A (es) | Combinación de agente antimitótico e inhibidor de aurora quinasa como tratamiento anticancerígeno | |
NI201200181A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
NI201200030A (es) | Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas. | |
GT201200220A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
AR086955A1 (es) | TERAPIAS COMBINADAS PARA EL TRATAMIENTO DE NEOPLASIAS MALIGNAS HEMATOLOGICAS UTILIZANDO INHIBIDORES DE PIRIDOPIRIMIDINONA DE PI3K/mTOR CON BENDAMUSTINA Y/O RITUXIMAB | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
UY33740A (es) | Método para tratar el cáncer de mama y cáncer de ovarios | |
CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
UY33221A (es) | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA | |
UY31756A1 (es) | Combinación del inhibidor hgf y el agonista pten para el tratamiento del cáncer | |
CL2012002858A1 (es) | Combinación farmacéutica que comprende 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencilamidazol-2-il-quinolin-2-ona y al menos un inhibidor de mtor; método de tratamiento; y uso para el tratamiento y la prevención de una enfermedad proliferativa tal como cáncer de mama, tumores neuroendocrinos y linfonas, entre otras. | |
CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
CR20140211A (es) | Terapia de combinación para cáncer de ovario | |
UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
UA99934C2 (ru) | Лечение рака молочной железы с помощью соединения 4-йодо-3-нитробензамида в комбинации с противоопухолевыми средствами |